Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Doubles Down On China With €70 Million Plant Upgrade, Sets Sights On Biosimilars In Shanghai

This article was originally published in PharmAsia News

Executive Summary

German firm looks to implement a “lean manufacturing” model to help offset rising costs in China.

Advertisement

Related Content

Biosimilars: A New Kind Of Innovation
AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Are China's Rising Labor Costs Good For Big Pharma?
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC077009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel